Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com


Channel Medsystems’ Cerene Cryotherapy Device Receives FDA’s Approval for Heavy

Shots: The FDA’s approval is based on CLARITY study assessing Cerene in 242 patients with excessive menstrual bleeding The CLARITY study results: @12mos. reduction in menstrual bleeding; m-pain score (0-2/10); no general anesthesia required; reduction in post-operative pain & intrauterine adhesions (81% and 79%); well tolerated without anesthesia The Cerene is a cryotherapy device that […]Read More


Astellas Signs a Research and License Agreement with Xencor for

Shots: Xencor to receive an upfront, development, regulatory & commercialization milestones and royalties on sales of product. Astellas to get exclusive WW license to develop and commercialize bispecific mAb for cancer Xencor to utilize its XmAb technology for the development of bispecific Ab candidates against Astellas’ targets & will take care of initial characterization of […]Read More


Boehringer Ingelheim (BI) to Acquire ICD Therapeutics for its MacroDel

Shots: Boehringer Ingelheim acquires ICD Therapeutics in all stock transaction, to utilize ICD’s MacroDel biologics-delivery platform to develop oncology therapies for intracellular delivery of macromolecules (peptides and proteins) The focus of the acquisition is to enhance Boehringer’s oncology portfolio with the development of therapies for intracellular targets for tumor cell types ICD’s MacroDel technology is […]Read More


Novartis to Acquire IFM Tre for its Clinical and Preclinical

Shots:  Novartis acquires IFM Tre, in all stock transaction for $1.575B. IFM Tre to receive $310M upfront & $1.265B milestones from Novartis. The transaction is expected to close in Q2’19 The focus of the acquisition is to expand Novartis’ immunomodulatory portfolio with the addition of IFM Tre’s one clinical (IFM-2427) and two preclinical programs of […]Read More


Takeda Signs a Multi-Target Agreement with StrideBio to Develop Gene

 Shots: StrideBio to receive $30M upfront & near term pre-clinical milestones, $680M as development and commercial milestones & royalties on global sales of products. Takeda to get rights for clinical development and commercialization of selected products developed StrideBio will take care of preclinical development & manufacturing of in vivo AAV based gene-therapies for Takeda’s three […]Read More


Mitsubishi Tanabe Pharma (MTPA) Collaborates with Massachusetts General Hospital (MGH)

Shots: Mitsubishi Tanabe Pharma (MTPA) enters into a collaboration with Massachusetts General Hospital (MGH) Neurological Clinical Research Institute (NCRI) to conduct ALS biomarker study for identification of biomarkers in patients with amyotrophic lateral sclerosis (ALS) The ALS biomarker study will evaluate 4 biomarkers enrolling 200 patients receiving Radicava (edaravone) for 24wks. across 40 sites and […]Read More


AstraZeneca Signs a Worldwide Development and Commercialization Agreement with Daiichi

Shots: Daiichi Sankyo to receive $1.35B upfront, $5.55B as regulatory & commercial milestones making the total deal value $6.9B. AstraZeneca to get WW co-development and co-commercialization rights for Daiichi’s trastuzumab deruxtecan (Ex- Japan) with equal cost & profit sharing The focus of the collaboration is to develop trastuzumab deruxtecan for HER2+ breast and gastric cancer […]Read More


Johnson & Johnson (J&J) Vision Launches Acuvue Oasys with Transitions

Shots: J&J Vision’s Acuvue Oasys with transitions light intelligent technology is evaluated in 1000 patients results demonstrated 67% performs better in doing physical activities, 55% feel stress exposing bright & harsh light, 56% adjust light condition quickly On Apr 11, 2018 J&J Vision collaborated with Transitions Optical Limited to develop Acuvue Oasys, a lens providing […]Read More


Apple Launches its Watch Series 4 Enabled with ECG App

Shots: The ECG app on Apple Watch Series 4 is evaluated in 600 patients resulted in 98.3% sensitivity in classifying AFib, 99.6% specificity in classifying sinus rhythm, 87.8% of recordings classified by the ECG app The irregular rhythm notification function was assessed in the Apple Heart study enrolled with 400,000 candidates and demonstrated 0.5% irregular […]Read More